Form 4: Sanara MedTech COO awarded 13,956 restricted shares

Sanara MedTech’s COO Jacob A. Waldrop received 13,956 restricted shares under the 2024 LTIP, vesting annually from 2027 to 2029, bringing his beneficial ownership to 24,755 shares.

Summary

• On 03/22/2026, Chief Operating Officer Jacob A. Waldrop acquired 13,956 shares of Sanara MedTech Inc. common stock via a restricted stock grant (Transaction Code: A).
• The grant price is $0, consistent with an equity award under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• Post-transaction beneficial ownership is 24,755 shares, held directly.
• Vesting occurs in three equal tranches: one-third on 03/22/2027, 03/22/2028, and 03/22/2029, contingent on continued employment through each date.
• The form was signed by Jacob A. Waldrop on 03/23/2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive, routine insider equity award that supports retention and alignment, without providing new information on operating performance.

Positives

• Equity grant aligns executive incentives with shareholder interests through multi-year vesting.
• No insider sale or disposition; transaction is an award (code A) rather than a sale.
• Clear, time-based vesting schedule supports retention and long-term focus.

Negatives

• Issuance of 13,956 new shares modestly increases share count and may cause slight dilution.
• Final ownership of the awarded shares is contingent on continued employment, introducing vesting uncertainty.

Risks

• Unvested restricted stock will only vest if the executive remains employed through 03/22/2027, 03/22/2028, and 03/22/2029; otherwise, unvested shares are subject to forfeiture.

Future Outlook

No financial guidance provided. The future vesting schedule indicates ongoing retention incentives for the COO through March 2029, contingent on continued employment.

Management Comments

• Restricted stock granted under the 2024 Omnibus Long-Term Incentive Plan will vest in three equal installments on 03/22/2027, 03/22/2028, and 03/22/2029, provided the executive remains employed through each date.

Industry Context

StockSavvy.ai notes insider equity awards with multi-year vesting are standard in medtech and broader healthcare, aligning executives with long-term shareholder value. Similar structures are common among small- and mid-cap peers in wound care and surgical products (e.g., MiMedx, Axogen, Organogenesis), with time-based vesting over three to four years being typical.

Comparison to Industry Standards

• Three-year, ratable vesting aligns with common small/mid-cap medtech practice; peers frequently use 3–4 year schedules for restricted stock or RSUs.
• Use of an omnibus long-term incentive plan is standard governance practice across healthcare peers; structure is in line with companies like MiMedx (MDXG) and Axogen (AXGN).
• Transaction is an equity grant (not an open-market purchase); compared to insider buys, grants carry a more neutral signaling effect, which is typical for routine compensation.

Related Party Transactions

• Restricted stock grant of 13,956 shares to the Chief Operating Officer under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.

Stakeholder Impact

• Shareholders: slight dilution from issuance of 13,956 restricted shares.
• Employees/Management: strengthens retention incentives for a key executive via multi-year vesting.
• Customers/Suppliers/Creditors: no direct operational or credit impact indicated.

Next Steps

• Monitor vesting milestones on 03/22/2027, 03/22/2028, and 03/22/2029, contingent on continued employment.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, insider transaction, restricted stock, equity compensation, long-term incentive plan, vesting schedule, beneficial ownership, chief operating officer